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Abstract  23 
 24 
An alcohol dehydrogenase from the halophilic archaeon Haloferax volcanii (HvADH2) has 25 
been engineered by rational design to broaden its substrate scope towards the conversion of 26 
a range of aromatic substrates, including flurbiprofenol, that is an intermediate of the non-27 
steroidal anti-inflammatory drug, flurbiprofen. Wild-type HvADH2 showed minimal activity 28 
with flurbiprofenol (11.1 mU/mg). A homology model of HvADH2 was built and docking 29 
experiments with this substrate revealed that the biphenyl rings of flurbiprofenol formed 30 
strong interactions with residues F85 and F108, preventing its optimal binding in the active 31 
site. Mutations at position 85 however did not increase activity. Site directed mutagenesis at 32 
position F108 allowed the identification of three variants showing a significant (up to 2.3-fold) 33 
enhancement of activity towards flurbiprofenol, when compared to wild-type HvADH2. 34 
Interestingly, F108G variant did not show the classic inhibition in the presence of (R)-35 
enantiomer when tested with rac-1-phenylethanol, underling its potential in racemic 36 
resolution of secondary alcohols.  37 
 38 
Abbreviations 39 
ADH (alcohol dehydrogenase); F-MBA (fluoro-methyl benzyl alcohol), 2-Phe-1-prop (2-phenyl-1-40 
propanol), 4-Phe-2-But (4-phenyl-2-butanol); WT (wild-type); HvADH2 (ADH2 from Haloferax volcanii) 41 
 42 
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 43 
Introduction  44 
 45 
Enzymes are appealing as a ‘green’ adjunct to chemical synthesis of pharmaceutical building 46 
blocks because of their broad specificity, enantioselectivity and ability to work under process 47 
conditions [1]. Found in all three domains of life, alcohol dehydrogenases (ADHs) are 48 
members of the oxidoreductase family, which catalyze the interconversion of primary and/or 49 
secondary alcohols into aldehydes and ketones, respectively [2]. A recent review details the 50 
staggering applications of ADHs in the production of pharmaceutical building blocks [3]. 51 
Codexis described the evolution of Lactobacillus kefir ADH towards the enantiopure 52 
intermediate of the anti-depressant, (S)-duloxetine, with yields as high as 150 g/L [4].  53 
Many additional examples of enzyme engineering applied to ADHs, which have led to variants 54 
suitable for industrial applications, have been reported in the literature [5-7]. Sequence 55 
alignments of protein families identify potential ‘hot-spots’ for mutagenesis as non-conserved 56 
positions; they are then further probed by homology modelling and in silico docking [8]. A 57 
site-directed mutagenesis strategy has applied for redesigning substrate specificity in 58 
glutamate dehydrogenase from Halobacterium salinarum [9]. The substitutions K89L, A163L 59 
and S367A converted this enzyme into a dehydrogenase accepting L-methionine, L-norleucine 60 
and L-norvaline as substrates. Biocatalytic strategies employing ADHs have already been 61 
reported to produce 2-arylpropionic acids and the corresponding derivatives [10-13]. 62 
Hyperthermophilic SsADH-10 from Sulfolobus solfataricus was applied to the enzymatic 63 
reduction and racemization of 2-arylpropionaldehydes [14]. 64 
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 65 
In a previous study, HvADH2 from Haloferax volcanii (wild-type, WT) showed an unusually 66 
broad substrate specificity, with good activity with medium-chain alcohols, modest activity 67 
with secondary alcohols and also significant activity with benzyl alcohol [15-17]. Later studies 68 
into the solvent tolerance and immobilization of HvADH2 prompted a deeper investigation of 69 
the substrate scope of HvADH2 [18-19]. HvADH2 showed some activity with flurbiprofenol in 70 
a low concentration salt buffer to facilitate solubility.  71 
 72 
Results and discussion 73 
 74 
HvADH2 Homology model and docking analysis 75 
 76 
Previous characterization of HvADH2 showed that the enzyme has a broad substrate scope 77 
because it can accept medium-chain alcohols, has modest activity with secondary alcohols 78 
and retained 50% activity with the aromatic substrate, benzyl alcohol [17]. The potential of 79 
HvADH2 to reduce prochiral aromatic ketones was also investigated and it was found that 2-80 
phenylpropionaldehyde was readily accepted (S7 Fig.). The model of the 3D structure of 81 
HvADH2 was obtained by the SWISS-MODEL web-based server [20, 21] using the 82 
formaldehyde dismutase from Pseudomonas putida (PDB: 2dph) as the template (27% 83 
sequence identity with HvADH2) [22]. The quality of the HvADH2 homology model was 84 
assessed using the software ERRAT [23]: 30.1% of the protein structure model could be 85 
rejected at a 95% confidence level (as compared to a threshold of 5% rejection for a high 86 
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quality model), but these (less accurate) regions are located on the protein surface and do 87 
not affect the overall conformation and substrate binding at the active site (S1 Fig.). The 88 
quality of the model was assessed by several bioinformatic tools that confirmed it as a reliable 89 
model (see supplementary materials, S2 Fig.). 90 
The NAD+ cofactor and the conserved catalytic Zn2+ ion were modelled into the HvADH2 91 
model based on their position and conformation observed in the structure of the 92 
formaldehyde dehydrogenase from Pseudomonas putida (PDB: 1kol, 26% sequence identity 93 
with HvADH2) [24]. HvADH2 possesses the typical Rossmann binding motif found in NAD-94 
binding enzymes.  95 
Docking studies with the secondary aromatic alcohol, (S)-1-phenylethanol, ((S)-1-PheOH) 96 
allowed the identification of the residues involved in the substrate binding at the active site 97 
of HvADH2. Two phenylalanine residues in position 85 and 108 (F85 and F108), at the top of 98 
the active site, were identified as being important for substrate binding. These residues, 99 
together with G294, form a hydrophobic pocket for the bulky aromatic ring of the substrate: 100 
in particular, F108 participates in - stacking interactions with the aromatic ring of (S)-1-101 
PheOH. The polar hydroxyl group of the substrate is located in a polar region of the active site 102 
lined by E49, D144 and S40 which forms a H-bond with oxygen of (S)-1-PheOH (Fig. 1). 103 
HvADH2 showed a specific activity of 1200 mU/mg with (S)-1-PheOH under standard assay 104 
conditions (while with 10 mM benzyl alcohol, 1 mM NADP+, 50 mM glycine-KOH, pH 10.0, the 105 
activity was 2300 mU/mg). The aspecific van der Waals interactions provided by the two Phe 106 
residues could explain the promiscuous activity of HvADH2 on aromatic substrates.  107 
 108 
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 109 
Although flurbiprofenol has significantly increased bulk in the side chain, the docking analysis 110 
shows that the mode of binding is very similar to (S)-1-PheOH. This is because the additional 111 
aryl ring of the ligand is placed at the active site entrance, in contact with bulk solvent. The 112 
hydroxyl group of the substrate is still within H-bonding distance to S40 and is 3.7 Å from the 113 
active site Zn2+ ion. The activity of purified wild-type HvADH2 toward 1 mM rac-flurbiprofenol 114 
(2 M KCl, 30% MeOH to facilitate solubility) is 11.1 mU/mg. The racemic mixture of this alcohol 115 
was used since it was produced by the synthetic procedure employed (ESI section 5). Based 116 
on the HvADH2-substrate complex model, this >100-fold drop in specific activity relative to 117 
(S)-1-PheOH could be explained by non-optimal positions of the reactive carbon atom of the 118 
substrate and the C4 of the cofactor NAD+ (Fig. 1C). Mutagenesis of F85 and F108 (i.e., 119 
substitution with a smaller residue) could result in a shorter distance between these two 120 
reactive atoms, thus affecting the catalytic activity of the enzyme by facilitating hydride 121 
transfer.    122 
 123 
 124 
Fig. 1 Three-dimensional model of HvADH2 active site in complex with different docked 125 
ligands. A) Complex with (S)-1-PheOH. B) LigPlot analysis of the interactions between docked 126 
(S)-1-PheOH and HvADH2 model. The substrate is in purple. Hydrophobic contacts are shown 127 
as dark red arches. C) Complex with (S)-flurbiprofenol. D) Complex with (S)-flurbiprofenol, 128 
surface representation. The ligands are represented as white sticks or spheres. The NAD+ 129 
cofactor is in yellow and Zn2+ is represented as a pink sphere. Important residues are shown 130 
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in green; the C of G294 is shown as a sphere. The - staking interactions are shown by 131 
dotted lines and H-bonds by dashed lines. 132 
 133 
 134 
Sequence alignment analysis 135 
 136 
Bio-prodict 3DM database was used for the alignment of over 14000 sequences (HvADH2 no. 137 
D4GP73) to determine the conservation degree of the two identified phenylalanine residues 138 
(top 9 homologues shown in Fig. 2) [25]. Across the alignment, the amino acid distribution at 139 
position 88 (numbering is per the 3DM database corresponding to F85 in HvADH2) was 17% 140 
phenylalanine, 16% proline and 28% was a gap. Position i1e (corresponding to F108) was less 141 
conserved in the alignment since it was found in only a limited pool of 400 sequences: the 142 
percentage of phenylalanine residues at this position was 9% (39% lysine, 21% arginine, and 143 
9% phenylalanine with no gaps). Both positions seem to show a low degree of conservation 144 
pointing to a role in definition of the enzyme’s substrate preference: both positions were 145 
subjected to mutagenesis to investigate their role in substrate binding. 146 
 147 
 148 
Fig. 2 Sequence alignment of HvADH2 with top 9 homologues. 3KRT: putative crotonyl CoA 149 
reductase from Streptomyces coelicolor. 1KOL: Formaldehyde dehydrogenase from 150 
Pseudomonas putida. 2DPH: Formaldehyde dismutase from Pseudomonas putida. 1HF3: liver 151 
alcohol dehydrogenase from Equus caballus. 1H2B alcohol dehydrogenase from Aeropyrum 152 
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pernix. 4A10: 2-octenoyl-CoA carboxylase reductase from Streptomyces sp. JS360. 2CDB: 153 
glucose dehydrogenase from Sulfolobus solfataricus. 1F8F: benzyl alcohol dehydrogenase 154 
from Acinetobacter calcoaceticus. 1MAO: glutathione-dependent formaldehyde 155 
dehydrogenase from Homo sapiens. 156 
 157 
 158 
Site-directed mutagenesis of F85 and simultaneous site saturation of F85 and 159 
F108 160 
 161 
To investigate the significance of F85, four mutations were investigated: a conservative F85Y 162 
variant as well as more challenging F85A, F85V and F85R substitutions. F85Y was the only 163 
variant which retained activity and was tested with a range of substrates, including 164 
flurbiprofenol. Activities were determined for HvADH2 wild-type and F85Y variant crude 165 
lysates; substrate concentration was fixed at 10 mM for benzyl alcohol and enantiopure 166 
molecules or 20 mM for racemic ones. No activity was detected with flurbiprofenol and the 167 
variant enzyme. The reference 100% activity with BzOH and wild-type HvADH2 refers to 247 168 
mU/mg whereas 280 mU/mg with F85Y. In all cases, activity for F85Y variant was lower 169 
compared to wild-type: F85Y retained 50% activity with (S)-1-PheOH, whereas wild-type 170 
retained 73%. F-MBA was poorly accepted by both wild-type (17%) and F85Y (9%). While 2-171 
Phe-1-Prop was an excellent substrate for wild-type (98%), activity dropped with F85Y (16%). 172 
Wild-type activity with 4-Phe-2-But was 53% compared to just 8% with F85Y.  173 
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Site-saturation mutagenesis was also performed at both sites, F85 and F108, simultaneously 174 
and screened for activity with flurbiprofenol (ESI page 4). From multiple rounds of screening, 175 
a double variant identified as F85AF108G was isolated as the best hit, and the substrate scope 176 
was further investigated. Docking (S)-flurbiprofenol with F85AF108G showed the correct 177 
conformation of the distal phenyl ring. Activity of HvADH2 F85AF108G in the crude extract 178 
was 30% higher with flurbiprofenol when compared to wild-type but when purified, this 179 
activity diminished and was therefore deemed a false positive. Since site directed and site 180 
saturation of F85 did not yield an improved variant, we focused on F108.  181 
 182 
Site directed mutagenesis of F108 and screening with flurbiprofenol  183 
 184 
Mutations at position F108 were evaluated initially by in silico modelling and docking with (S)-185 
flurbiprofenol. HvADH2 variants F108A, F108G, F108L, F108P, F108V, F108W, and F108Y were 186 
modelled and tested in silico for affinity with (S)-flurbiprofenol, the main differences in 187 
theoretical binding energy are reported in Table ES.2. F108V was predicted as the best variant 188 
because of its ability to accommodate the biphenyl moiety of (S)-flurbiprofenol (S9 Fig. A-B). 189 
In silico results obtained with F108W, F108Y, F108P, and F108L variants were also indicative 190 
of improved binding. F108A substitution (S9 Fig. C-D) appeared to open the binding pocket 191 
and allow the distal aryl ring to point towards bulk solvent, which was not optimal in the wild-192 
type enzyme.  193 
All these variants were engineered by site directed mutagenesis, expressed and purified (ESI 194 
page 10, small scale expression and purification) and activities are reported in Table 1. 195 
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Contrary to the indications gathered from the docking, F108A and F108G showed no activity 196 
with rac-flurbiprofenol, whereas F108W, which introduces more steric bulk into the active 197 
site, was slightly more active than WT (13.8 vs. 11.1 mU/mg). The specific activity of F108Y 198 
variant (the most conservative substitution) on the latter compound was virtually identical to 199 
WT HvADH2. The F108L variant (docking shown in Fig. 3) showed the highest specific activity 200 
of 25.4 mU/mg, a 2.3-fold increase in activity compared to WT enzyme. To investigate if a 201 
non-conserved mutation would be beneficial, a methionine variant was prepared (F108M). 202 
While F108M HvAFH2 was active with EtOH (1103 mU/mg), it did not show activity towards 203 
flurbiprofenol.  204 
  205 
Table 1. Activity of purified wild-type and F108 variants of HvADH2 with rac-flurbiprofenol.  206 
Variant Specific activity (mU/mg protein) 
WT 11.1  0.2 
F108G 0 
F108A 0 
F108V 16.2  0.1   
F108W 13.8  0.3 
F108L 25.4  0.2 
F108Y 11.7  0.3 
F108P 0 
F108M b.d. 
b.d. = below detection 207 
  
 
11 
 208 
 209 
Fig. 3 F108L docked (F85 blue spheres and L108 purple spheres; NAD+, yellow sticks) with (S)-210 
flurbiprofenol (white spheres), surface view. The distance from the hydroxyl oxygen to the 211 
catalytic zinc (O-Zn) is 4.4 Å, and the distance from the substrate α-carbon to the C4 of the 212 
nicotinamide ring (αC-C4), is 5.9. 213 
 214 
 215 
In order to clarify the structure-function relationships modulating HvADH2, purified F108G 216 
variant and wild-type HvADH2 were assayed with BzOH, rac-1-PheOH, (S)-1-PheOH and (R)-217 
1-PheOH (Fig. 4). Even if F108G HvADH2 was not active with flurbiprofenol, the dramatic 218 
change induced in the active site yielded a fully folded protein with 40% activity with respect 219 
to the WT, i.e. 800 mU/mg with 10 mM benzyl alcohol (see ESI for details about the expression 220 
and purification).  221 
 222 
 223 
Fig. 4 Substrate specificity of purified F108G variant compared to WT HvADH2. Buffer 224 
conditions: 4 M KCl, 50 mM Gly-KOH, pH 10.0. 225 
 226 
 227 
Remarkably, F108G showed an increase in activity with rac-1-PheOH with respect to the WT 228 
(680 and 460 mU/mg respectively). However, with optically pure (S)-1-PheOH, WT was clearly 229 
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more active (1200 mU/mg), whereas F108G maintained almost unaltered activity (620 230 
mU/mg). To investigate if the opposite enantiomer was accepted as substrate, (R)-1-PheOH 231 
was tested with both WT and F108G HvADH2 but showed negligible activity (70 and 50 232 
mU/mg, respectively). Addition of 10 mM of (R)-1-PheOH to the standard reaction mixture 233 
(10 mM benzyl alcohol) reduced the WT HvADH2 specific activity down to 840 mU/mg (in 234 
comparison to the 2,300 mU/mg of the original one), while, in the case of the F108G variant, 235 
the activity was virtually unaffected. Docking of (R)-1-PheOH to wild-type HvADH2 shows a 236 
clear interaction between the aromatic side chain of the substrate and F108 (Fig. 5A) which 237 
is not present in the variant harbouring F108G (Fig. 5B). On closer inspection of the docking, 238 
in the wild-type model, the distance between the reactive carbon atom of the substrate and 239 
the C4 of the cofactor NAD+ is 5.7 Å. This distance is shortened to 4.2 Å in the F108G model. 240 
The experimental evidence together with the in silico predictions strongly suggest that 241 
removal of the bulky side-chain from F108 in the glycine variant creates a cavity in the active 242 
site. This space could allow the binding of the preferred enantiomer while still housing the 243 
(R)-1-PheOH without hampering catalytic efficiency of the enzyme in the presence of a 244 
racemic mixture. 245 
 246 
 247 
Fig. 5 Docking of (R)-1-PheOH (white spheres). A) Catalytic site of the WT enzyme (F85 and 248 
F108 green spheres, NAD+, yellow sticks) shows stabilization of the substrate aromatic ring by 249 
F108. The distance from the hydroxyl oxygen to the catalytic zinc (O-Zn) is 4.6 Å, and the 250 
distance from the substrate α-carbon to the C4 of the nicotinamide ring (αC-C4), is 5.7 Å. B) 251 
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Catalytic site of the F108G variant. The distance from the hydroxyl oxygen to the catalytic zinc 252 
(O-Zn) is 2.5 Å, and the distance from the substrate α-carbon to the C4 of the nicotinamide 253 
ring (αC-C4), is 4.0 Å. 254 
 255 
 256 
Experimental  257 
 258 
Expression and purification of wild-type and variants of HvADH2 in Haloferax 259 
volcanii 260 
 261 
The transformation, production, purification and identification of wild-type and variants of 262 
HvADH2 were performed as described previously [16, 17]. Small scale expression and 263 
purification are detailed in the ESI page 8. 264 
 265 
Enzyme assays 266 
 267 
Enzyme activity was assayed as production of the NADPH cofactor detected at 340 nm, 268 
measured in intervals of 1 min for 20 min at 50 ˚C (Epoch 2 microplate reader, BioTek, Bad 269 
Friedrichshall, Germany; 96 Well Clear Flat Bottom UV-Transparent Microplate Corning®, 270 
3635). All kinetic assays were performed in triplicate. The blank was treated by adding the 271 
storage buffer (3 M KCl, 100 mM Tris-HCl, pH 8.0) instead of enzyme. 272 
 273 
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HvADH2 Homology modelling 274 
 275 
The web-based server SWISS-MODEL was used to build the model of HvADH2 with a GMQE 276 
score of 0.68 [20, 21]. The details for the docking and inspection are mentioned in the 277 
supporting information (S1 File). 278 
 279 
 280 
HvADH2 Mutant generation 281 
 282 
The adh2 gene harboured in the pTA963 plasmid was mutated using the QuikChange 283 
Lightning Multi Site-Directed Mutagenesis Kit provided by Agilent Technologies®. Details of 284 
the PCR reaction and the oligonucleotide primers are detailed in the supporting information 285 
(S1 File and S1 Table).  286 
 287 
Conclusions  288 
 289 
Rational design coupled with molecular modelling were applied here for the generation of 290 
several site directed variants of HvADH2. Building a homology model of HvADH2 allowed the 291 
identification of two phenylalanine residues, at position 85 and 108, which were proposed to 292 
be critical residues for the binding of 1-PheOH due to π-π stacking interactions. Docking (S)-293 
flurbiprofenol (an intermediate for the non-steroidal anti-inflammatory drug, flurbiprofen) 294 
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into the wild-type HvADH2 model showed the unfavourable conformation of the distal aryl 295 
ring due to the interactions with the two Phe residues.  296 
F85 appears critical for the stabilization in the binding pocket of small aromatic substrates, 297 
whereas the absence of the side chain of F108 facilitates the binding of secondary aromatic 298 
alcohols (i.e., 1-PheOH). Site saturation mutagenesis was performed at both sites to make a 299 
small, diverse library. However, several rounds of screening failed to identify an improved 300 
variant. The best hit, F85AF108G lost all activity after purification. It was then decided to 301 
perform site directed mutagenesis at each site, independently of each other. F85 tolerated 302 
only conservative mutations such as F85Y which was active with all tested substrates albeit 303 
less than the WT HvADH2. Sequence alignments confirmed that F108 was indeed a less 304 
conserved position and site directed mutagenesis was performed following in silico modelling 305 
and docking to predict improved variants. Among the generated single point variants, F108W, 306 
F108Y and F108L accepted flurbiprofenol with enhanced activity compared to wild-type 307 
HvADH2; specifically, F108L had a 2.3-fold improvement in activity. The F108G variant showed 308 
surprisingly no activity with flurbiprofenol while retaining 40% of the WT activity with benzyl 309 
alcohol. Further testing of this variant with rac-1-PheOH indicated that the enzyme performed 310 
significantly better than the WT possibly due to the larger binding site created. (R)-1-PheOH 311 
is not a substrate for the glycine variant nor for the WT HvADH2. This compound is a strong 312 
competitive inhibitor of the latter; whereas it is not able to bind to the F108G variant possibly 313 
due to the key role of F108 in stabilising the aromatic moiety of the substrate. In silico docking 314 
and site directed mutagenesis were successfully applied to improve enzymatic activity with a 315 
bulky, aromatic substrate which was poorly accepted by the wild-type enzyme. This model-316 
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guided mutagenesis was performed on a protein for which the closest structural analogue 317 
had less than 30% similarity in the sequence, underlying the power of this technique.  318 
 319 
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S1 Fig. Quality of the HvADH2 model. Regions of the structure that can be rejected at the 396 
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S7 Fig. HvADH2 substrate specificity with aromatic ketones at pH 8.0 and 10.0. Substrate 406 
concentration was fixed at 10 mM in 4 M KCl, 50 mM glycine buffer, pH 10.0. 407 
S8 Fig. SDS-PAGE gel of HvADH2 variants purification on a Ni-NTA mini-column. Lane 1: 408 
broad range protein marker Precision Plus Kaleidoscope, (10-250 kDa); Lane 2: WT; Lane 3: 409 
F108Y; Lane 4; F108L Lane 5; F108W.  410 
S9 Fig A-D. Docking analysis of (S)-flurbiprofenol to F108x HvADH2 variants. Panel A: Docking 411 
of (S)-flurbiprofenol to F108V HvADH2; panel B: surface view of panel A. The distance from 412 
the hydroxyl oxygen to the catalytic zinc (O-Zn) is 4.3 Å, and the distance from the substrate 413 
α-carbon to the C4 of the nicotinamide ring (αC-C4), is 6.7; panel C: docking of (S)-414 
flurbiprofenol to F108A HvADH2; panel D: surface view of panel C. F85 is represented in 415 
purple spheres and F108 by lilac spheres, NAD+ by yellow sticks and (S)-flurbiprofenol by white 416 
spheres. The distance from the hydroxyl oxygen to the catalytic zinc (O-Zn) is 4.8 Å, and the 417 
distance from the substrate α-carbon to the C4 of the nicotinamide ring (αC-C4), is 7.1.   418 
S10 Fig. SDS-PAGE analysis of HvADH2 F108G purification from Haloferax volcanii strain 419 
H1325. Lane 1: broad range protein marker P7702S, (2-212 kDa); Lane 2: crude lysate; Lane 420 
3-10: eluted fractions 1-8 respectively. The band corresponding to F108G is indicated by the 421 
arrow. 422 
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